Now approved in the EU, Duvyzat offers an important treatment option for delaying Duchenne muscular dystrophy (DMD) disease ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Advancements in gene therapy for Duchenne muscular dystrophy (DMD) have improved the outlook for some patients, but further ...

Cardiac complications in Duchenne muscular dystrophy (DMD) are the result of cardiac muscle involvement that accompanies the ...

Satellos CEO Frank Gleeson said: “Given the short 28-day treatment window ... of functional muscle tissue. There are some approved gene therapies for DMD, including Roche and Sarepta’s ...

Satellos Bioscience Chief Scientific Officer discusses early-stage trials of the company's Duchenne muscular dystrophy drug, ...

But, the longevity of the treatment is a concern for providers ... of treating patients earlier.” Though there is no requirement for DMD newborn screening in Arizona, Castle has been active ...

Capricor's lead asset, deramiocel, targets DMD-related cardiomyopathy and faces ... This is in Phase 1 development. Then there are engineered exosomes for RNA, protein, and small molecule delivery.

Children with a rare type of muscular dystrophy received calls from doctors ... Emily Reuben and Alex Johnson, founders of Duchenne UK, said: “There’s something worse than having no treatment - and ...

Children with a rare type of muscular dystrophy received calls ... founders of Duchenne UK, said: “There’s something worse than having no treatment - and that’s having a treatment, available ...

Dystrophin's isoforms are thought to contribute variably to neuropsychiatric disorders, behavioral disorders, and ...